


# RADIOLIGAND THERAPY FOR NEUROENDOCRINE CANCERS

## WHAT IS RADIOLIGAND THERAPY ?


Radioligand therapy (RLT) is a targeted cancer treatment that delivers radiation directly to cancer cells. It uses a vector (the “ligand”) designed to attach to a specific receptor on cancer cells. Once attached, it releases a controlled amount of radiation to damage those cells.




## IMAGING AND THERAPEUTIC USE

### IMAGING

The first step is to visualize cancer cells and confirm that the receptors is sufficiently expressed for effective treatment, using a low radioactive tracer dose for diagnostic imaging.




### THERAPY



If receptors are present, the treatment can be given and the therapeutic radioactive molecule will target directly the cancer cells.

## HOW IS IT ADMINISTERED?



**Radioligand therapy is given through a drip into a vein.**

As soon as your radiation level is in a safe range, you'll be allowed to go home.

## IS RADIOLIGAND THERAPY SAFE?

Radioligand Therapy (RLT) has been **used for many years in the care of neuroendocrine tumors.**


The doses given are **precisely calculated** and regulated to ensure patient safety. The radioactivity will gradually decay and leave your body over the following hours and days.



You may also **hear Radioligand Therapy** referred to as **PRRT** or **Peptide Receptor Radionuclide Therapy, RLT, Radiopharmaceutical** or **Molecular Radiotherapy** or by **specific treatment names** such as Lutetium-177 DOTATATE

## WHAT ARE NEUROENDOCRINE CANCERS ?

Neuroendocrine tumors (NETs) are a diverse group of cancers that arise from neuroendocrine cells, which have features of both nerve cells and hormone-producing cells. It can be sorted in two categories:



- **Neuroendocrine Tumours (NETs)** are usually slower-growing and well-differentiated. They often express somatostatin receptors (SSTR). NETs are graded by growth speed: G1 (slow), G2 (intermediate), and G3 (faster but still well-differentiated).
- **Neuroendocrine Carcinomas (NECs)** are typically fast-growing, poorly differentiated, and more aggressive.

## AM I ELIGIBLE FOR RADIOLIGAND THERAPY?

Radioligand Therapy (RLT) is generally used for NETs, not NECs, and may be considered if:

- The tumour is well-differentiated (NET)
- Imaging confirms sufficient receptor expression (SSTR2 positive)
- Systemic treatment is needed

Eligibility depends on tumor type, previous treatments, and overall health. You can discuss this potential therapy with your medical team.

## WHAT RESULTS CAN BE EXPECTED?

RLT is not usually a cure.

However, it may:

- Slow tumour growth
- Reduce tumour burden
- Improve hormone-related symptoms
- Reduce pain or discomfort
- Help maintain quality of life



## FURTHER SUPPORT AND INFORMATION

**INCA** International  
Neuroendocrine  
Cancer Alliance

The INCA website provides information and links to national patient organisations and support groups.



Visit our Website for more info:  
[www.oncidiumfoundation.org](http://www.oncidiumfoundation.org)  
or contact us at:  
[care@oncidium-life.org](mailto:care@oncidium-life.org)

